"ID";"Original Title";"Title";"Summary";"Contact";"Citation";"URL Scientific Article";"More References";"Keywords";"Field of Research";"Method/Model";"Year of Publication";"Month of Publication";"Date of Editing"; "540";"Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation";"Start up developes T cell silencer for autoimmune diseases";"Mistargeted T-cell activity can lead to episodic inflammatory reactions, which are a characteristic of autoimmune diseases, thus prevention of these cascades is an important therapeutic goal. Common immunosuppressants or cortisone do not act at the origin of the disease and therefore cannot stop its progression. Based on in vitro experiments with human peripheral blood cells from voluntary donors, so-called T-cell silencers could be identified. These may have the potential to prevent diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis directly at its origin, at the unwanted T cell activity.";"Thomas Harder, Otto-von-Guericke University Magdeburg, Magdeburg, Germany";"Thomas Harder et al. Cell Communication and Signaling 2014";"https://biosignaling.biomedcentral.com/articles/10.1186/s12964-014-0074-6";"Tranquil Immune GmbH, https://www.tranquil-immune.de/";"drug discovery, multiple sclerosis, T cells, inflammation, immune response, autoimmune diseases";"Allergology, Rheumatology, Autoimmune, Haematology, Immunology, Drug development and testing";"Cell culture, Tissue models";"2014";"12";"2021-04-30 15:07:40";